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COMMENTARY Open Access
The whole truth and nothing but the truth:
the need for full reporting of randomised
trials
Rupert M. Pearse1,2
Abstract
The use of cardiac output monitoring to guide fluid and inotropic therapy in surgical patients has remained a
controversial topic for more than 40 years. The reasons for this are numerous and complex, but key amongst them
is the interplay between poor research methodology and the likely selective reporting of randomised trials. In this
issue of Perioperative Medicine, we find a very unusual report, one which describes a randomised trial stopped for
futility after the recruitment of only a small proportion of the target patient sample (Jammer et al. Periop Med). The
authors offer no statistical analysis of their findings but simply an explanation of what went wrong. On the face of
it, this exercise would seem to offer little of value to the general reader. How can publication of the findings of an
unsuccessful trial contribute to the evidence base on this topic? To understand this, we must delve a little deeper
into the evidence and see how these trials were designed.
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Background
Cardiac output-guided haemodynamic therapy is a com-
plex intervention consisting of one or more therapeutic
agents (fluid and/or inotropes), a monitoring device, and
a human who interprets the data provided by this device
using an algorithm, adjusting therapy doses accordingly.
Trials of complex interventions have a particular set of
limitations, so much so that in the UK, the Medical Re-
search Council has developed methodological guidance
on the design of such trials [1]. However, the sad truth is
that many previous randomised trials of cardiac output-
guided haemodynamic therapy have been of very poor
methodological design. The key weaknesses are small
patient samples recruited in single centres, use of sub-
jective clinical outcome measures with no observer
blinding to study group allocation, and the provision of
control group care according to alternative algorithms
which may be better or worse than usual clinical prac-
tice. These limitations are easily found, even amongst
the most recent randomised trials, but if we search
reports from more than 15 years ago, we can find far
more serious problems including a lack of clarity around
which patients were randomised to which treatment,
failure to include the outcomes of all trial participants in
an ‘intention to treat’ analysis, and undeclared links to
commercial partners. These problems do not affect every
published trial but are frequent enough to fuel long run-
ning arguments between experts in the field and to
undermine wider confidence in the evidence base. Doc-
tors are left uncertain as to the clinical benefits and cost
effectiveness of the treatment and may be disproportion-
ately influenced by one or two trial reports, often be-
cause these reflect their own prejudicial views. It is
important that we recognise that this evidence base is
flawed and cannot justify any lasting change in practice
towards the use of cardiac output monitoring. There are
two key reasons why the publication of the findings of
unfinished trials will help to resolve this problem.
Discussion
For this particular intervention, futility of the trial is
likely to be associated with futility of the treatment. The
investigators struggled to identify enough eligible pa-
tients for their trial and struggled to ensure they
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received the trial intervention. If we do not publish the
results of unfinished trials, we will bias reporting to-
wards ‘positive’ trials and create the false impression of
an overall clinical benefit. Alternatively, if the outcome
data from such trials are publically available, they may
still be included in systematic reviews even if not sub-
jected to statistical testing in the primary report. This
counters the effect of publication bias. The second rea-
son is less scientific but probably more important. Con-
fidence in the evidence base has been systematically
undermined by long running arguments between aca-
demics, many of whom have one vested interest or an-
other in cardiac output guided therapy being shown to
work. Counterintuitively, the publication of a report
which does nothing to flatter those of us who work in
this field does not undermine wider confidence in the
evidence base but proves to the reader that a full and
frank disclosure is taking place. All is in the public do-
main, nothing is hidden from sight, and all the relevant
information can be taken into account as we formulate
a view of the evidence. Jammer and colleagues must be
congratulated for placing their work in the public do-
main, and the journal editors should be applauded for
publishing it.
Conclusion
After 40 years and more than forty randomised trials, we
remain uncertain about the perceived benefits of cardiac
output-guided haemodynamic therapy. The findings of
our own large multi-centre trial simply reinforce this un-
certainty [2]. Only a very large multi-centre trial can pro-
vide the definitive answers we seek. Such a trial seems
unlikely to happen, unless supported by both industry and
major public funder(s). If this robust evidence cannot be
provided, we should consider whether cardiac output
monitoring adds value for our patients or is simply a dis-
traction to the provision of high quality perioperative care.
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